Valve Disease, Aortic

4

Review clinical trials related to Valve Disease, Aortic. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

DELINEATE-Prospective

Heart disease is the leading cause of death in the United States, and echocardiography (or "echo") is the most common way doctors look at the heart. Echo is safe, painless, and can detect major heart problems, including weak heart pumping and valve disease. Valve disease, especially aortic stenosis (narrowing) and mitral regurgitation (leakage), is common in older adults but often goes undiagnosed. While echo is the main tool for finding valve problems, it takes time, requires expert training, and results can vary between readers. Recent advances in artificial intelligence (AI), especially deep learning (DL), have shown promise in automatically analyzing heart images. However, past research hasn't fully tackled key echo techniques-like color Doppler and spectral Doppler-that are crucial for measuring how blood moves through heart valves. AI tools also face challenges in being used in everyday medical practice because of workflow issues, lack of real-world testing, and concerns about how the algorithms make decisions. At Columbia University Irving Medical Center, researchers have built a large database of heart tests over the last six years and developed AI programs to analyze echocardiograms. The current study will test whether providing AI analysis to cardiologists in real time during echo reading can make the process faster and more consistent.

Participants needed: 50
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Columbia UniversityUpdated: Apr 16, 2026Locations: 1
Eligibility criteria

Attending cardiologist employed by Columbia University, ColumbiaDoctors, or NewY... [+1]

Physician in training (cardiology fellow or advanced imaging fellow)

Status: Not yet recruiting

Self-Expanding Hydra Transcatheter Heart Valve (THV) Series Versus Balloon-Expandable Devices for Valve-In-Valve Transcatheter Aortic Valve Implantation (TAVI) for Patients With Failed Surgical Aortic Bioprosthesis.

This is a prospective, randomised, international, multicentre, open-label, investigator-initiated study in patients undergoing valve-in-valve Transcatheter Aortic Valve Implantation (TAVI) for failed surgical aortic bioprosthesis. A total of 111 patients will be randomized in a 2:1 ratio, with 74 patients assigned to self-expanding Hydra THV Series and 37 patients assigned to BEV (Sapien THV Series and MyVal THV Series).

Participants needed: 111
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: National University of Ireland, Galway, IrelandUpdated: Apr 13, 2026Locations: 1
Eligibility criteria

Male or Female patient ≥18 years of age [+4]

Patients unwilling to provide an informed consent, or whose legal representative... [+13]

Status: Not yet recruiting

ArcFlex Sheath in TAVR Trial

TAVR is a crucial treatment method for aortic valve diseases. The requirements for the device to cross the aortic arch and for the bioprosthetic valve to be coaxial are quite high, and they are key steps for the success of the surgery. Investigators' aim is to evaluate the safety and effectiveness of a variable-bend sheath for the TAVR procedure.

Participants needed: 180
Trial details
Biological sex: AllType: InterventionalSponsor: Sun Yat-sen UniversityUpdated: Jan 6, 2026Locations: 1
Eligibility criteria

Judged by a professional cardiologist to require TAVR surgery [+3]

Presence of other valvular diseases requiring concurrent intervention. [+15]

Status: Recruiting

Allogeneic Valve Transplantation

Valves will be taken from hearts donated by organ donors, and implanted into patients who need a new heart valve.

Participants needed: 4
Trial details
Age: 30-50Biological sex: AllType: InterventionalSponsor: Boston Children's HospitalUpdated: Sep 24, 2024Locations: 1
Eligibility criteria

Patients requiring aortic, pulmonary, mitral or tricuspid valve replacement. [+7]

Age < 30 days [+17]